Search Results for: "Clinic Roundup"
-
Clinic Roundup
Optimer reported top-line data from the pivotal study last year. (See BioWorld Today, Nov. 12, 2008BioWorld Today | Tuesday, November 3, 2009 -
Clinic Roundup
Those findings, presented at the Obesity Society meeting in Washington, add to the top-line data presented earlier this year, which showed a significant weight loss in patients receiving one year of treatment with lorcaserin. (See BioWorld Today, Sept. 21, 2009...Top-line data from COR-I and COR-II were reported in July. (See BioWorld Today, July 21, 2009BioWorld Today | Wednesday, October 28, 2009 -
Clinic Roundup
Sangamo BioSciences Inc., of Richmond, Calif., said top-line data showed that its SB-509 demonstrated statistical significance in a Phase II diabetic neuropathy trialBioWorld Today | Wednesday, October 21, 2009 -
Clinic Roundup
Top-line data are expected in mid-December and, if positive, will form the basis for a new drug application filing in the second quarter of 2010BioWorld Today | Thursday, October 15, 2009 -
Clinic Roundup
Alkermes Inc., of Cambridge, Mass., reported top-line data from two Phase I trials of ALKS 33, an oral opioid modulator to treat addiction and other central nervous system disorders, showing that the drug was well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once-daily dosingBioWorld Today | Wednesday, October 14, 2009 -
Clinic Roundup
Nektar Therapeutics Inc., of San Carlos, Calif., said top-line data from a Phase II trial showed that of NKTR-118, an oral peripherally-acting opioid antagonist, increased spontaneous bowel movements over the baseline period, the study's primary endpointBioWorld Today | Tuesday, October 13, 2009 -
Clinic Roundup
Transdel Pharmaceuticals Inc., of La Jolla, Calif., reported positive top-line data from a Phase III trial of Ketotransdel, a topical formulation of nonsteroidal anti-inflammatory drug ketoprofen, showing that the study achieved statistical significance in the primary endpoint in the per protocol analysis of 252 patientsBioWorld Today | Wednesday, October 7, 2009 -
Clinic Roundup
Top-line data are expected late this year, and detailed data will be presented at a scientific conference next yearBioWorld Today | Tuesday, September 29, 2009 -
Clinic Roundup
Top-line data are expected by mid-2010BioWorld Today | Thursday, September 24, 2009 -
Clinic Roundup
Top-line data from the first trial are expected later this monthBioWorld Today | Thursday, September 10, 2009 -
Clinic Roundup
Array BioPharma Inc., of Boulder, Colo., reported top-line data from a Phase I trial of ARRY-403, a small-molecule glucokinase activator, in Type II diabetics, showing that it met its primary and secondary endpoints of safety, pharmacokinetics and glucose controlBioWorld Today | Wednesday, August 12, 2009 -
Clinic Roundup
Top-line data in each of the pivotal trials demonstrated that the drug met its primary objective of noninferiority and achieved high clinical cure rates compared to ceftriaxone in patients with moderate to severe pneumonia requiring hospitalizationBioWorld Today | Monday, June 22, 2009 -
Clinic Roundup
Top-line data from the trial were submitted to the FDA, and the company is in the process of finalizing the Phase III programBioWorld Today | Tuesday, June 9, 2009 -
Clinic Roundup
The company expects to announce top-line data in the first half of 2010BioWorld Today | Tuesday, April 7, 2009 -
Clinic Roundup
Preliminary top-line data are expected to become available in the fourth quarter for both studiesBioWorld Today | Wednesday, March 4, 2009 -
Clinic Roundup
The company previously reported top-line data from the trial showing that Corlux plus Risperdal resulted in statistically significant reduction in weight gain compared to Risperdal aloneBioWorld Today | Tuesday, February 24, 2009 -
Clinic Roundup
Top-line data were reported late last year, and final data have been submitted for presentation at the American Diabetes Association 2009 scientific sessions. (See BioWorld Today, Dec. 5, 2008BioWorld Today | Wednesday, February 11, 2009 -
Clinic Roundup
Arpida Ltd., of Reinach, Switzerland, reported top-line data of its Phase II intravenous-to-oral switch trial, which showed clinical cure rates of more than 90 percent following the step-down therapy with oral iclaprim administered after two days of initial treatment with intravenous vancomycin in patients with complicated skin and skin structure infections (cSSSI...PrGCD also is being studied in a pivotal, Phase III trial in naïve Gaucher's disease patients, with top-line data expected in theBioWorld Today | Monday, December 22, 2008 -
Clinic Roundup
Rib-X Pharmaceuticals Inc., of New Haven, Conn., reported positive top-line data from a Phase II trial of delafloxacin (RX-3341), an intravenous formulation of its anionic quinolone antibiotic, which showed that both doses (300 mg BID and 450 mg BID) were as efficacious as the FDA-approved dosing regimen for Tygacil (tigecycline, Wyeth) in complicated skin and skin structure infectionsBioWorld Today | Tuesday, December 9, 2008 -
Clinic Roundup
Top-line data is expected in the first half of 2009BioWorld Today | Friday, December 5, 2008
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.